GILD · Gilead Sciences, Inc. Healthcare −0.7% on Oct 16
Updated Oct 17 · 9 feeds behind: FDA drug approvals, 1 day, and 8 more · Every feed →
On this page The market view
Price chart Show price chart The interactive GILD chart (by TradingView) loads here.
Behind the stock
Recent disclosures Last 90 days · by disclosure date
Company insiders Insiders 0 buys11 sells
See who traded ↓ Company filings ↓ Is this unusual? ↓
Counts are trades, not people: one person's lots filed on the same day count as one trade. Trades can be disclosed weeks after they happen.
Our take 9 rules fired on GILD
In short: none of these rules has solid or some evidence yet, so they show no clear lean on GILD.
How each did in past tests, against similar stocks over 3 months. Past results don't predict future ones.
⚪ Not enough evidence · −0.1 pp vs similar · 17 signals on GILD · Open now
⚪ Not enough evidence · +4.4 pp vs similar · 5 signals on GILD
⚪ Not enough evidence · +8.6 pp vs similar · 4 signals on GILD
All 9 rules ⚪ Not enough evidence · +2.0 pp vs similar · 4 signals on GILD
⚪ Not enough evidence · +4.6 pp vs similar · 4 signals on GILD
⚪ Not enough evidence · +0.4 pp vs similar · 2 signals on GILD
⚪ Not enough evidence · +2.9 pp vs similar · 2 signals on GILD
⚪ Not enough evidence · +2.5 pp vs similar · 1 signal on GILD
⚪ Not enough evidence · +1.0 pp vs similar · 1 signal on GILD
🔒 The 0–100 score for GILD, and which of these rules are open on it right now
Members see one number for how strongly these rules agree on GILD, and the day each rule fired. Better-tested rules count more, and so do different kinds of filings that point the same way.
See pricing → Compare with this company’s history
Is disclosure activity unusual? See how many different insiders or members of Congress reported purchases or sales of GILD. Each bar covers 28 days, by disclosure date. Several trades by one person count once in each group and period.
Latest period: Sep 21, 2026–Oct 18, 2026 · UTC dates · today is excluded
Insider purchases 0 filers recorded Short history Insider sales 3 filers recorded Short history Congress purchases 0 filers recorded Within earlier range Congress sales 0 filers recorded Sparse history
Insider purchases
Short history
Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual.
Latest 28 days 0
Earlier median 0
Earlier range 0–0 Distinct filers per 28 days Scale: 0–1
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: Jun 16, 2026. Newest disclosure across this feed: Oct 16, 2026.
Earlier periods in the comparison: 3. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Insider sales
Short history
Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual.
Latest 28 days 3
Earlier median 4
Earlier range 3–4 Distinct filers per 28 days Scale: 0–4
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: Jun 16, 2026. Newest disclosure across this feed: Oct 16, 2026.
Earlier periods in the comparison: 3. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Congress purchases
Within earlier range
This count falls within the range of the 12 earlier comparable periods in this view.
Latest 28 days 0
Earlier median 0
Earlier range 0–1 Distinct filers per 28 days Scale: 0–1
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: May 19, 2014. Newest disclosure across this feed: Oct 15, 2026.
Earlier periods in the comparison: 12. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Congress sales
Sparse history
Only 1 of 12 earlier periods had activity. That is too little recurring activity to label this count unusual.
Latest 28 days 0
Earlier median 0
Earlier range 0–1 Distinct filers per 28 days Scale: 0–1
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: May 19, 2014. Newest disclosure across this feed: Oct 15, 2026.
Earlier periods in the comparison: 12. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Exact counts, dates and filings for all four categories Insider purchases · Short history Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 0; range: 0–0.
Insider purchases: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 — Unavailable Nov 17, 2025–Dec 14, 2025 — Unavailable Dec 15, 2025–Jan 11, 2026 — Unavailable Jan 12, 2026–Feb 8, 2026 — Unavailable Feb 9, 2026–Mar 8, 2026 — Unavailable Mar 9, 2026–Apr 5, 2026 — Unavailable Apr 6, 2026–May 3, 2026 — Unavailable May 4, 2026–May 31, 2026 — Unavailable Jun 1, 2026–Jun 28, 2026 0 Partial; excluded Jun 29, 2026–Jul 26, 2026 0 Within stored history Jul 27, 2026–Aug 23, 2026 0 Within stored history Aug 24, 2026–Sep 20, 2026 0 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 0 Within stored history
Insider sales · Short history Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 4; range: 3–4.
Insider sales: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 — Unavailable Nov 17, 2025–Dec 14, 2025 — Unavailable Dec 15, 2025–Jan 11, 2026 — Unavailable Jan 12, 2026–Feb 8, 2026 — Unavailable Feb 9, 2026–Mar 8, 2026 — Unavailable Mar 9, 2026–Apr 5, 2026 — Unavailable Apr 6, 2026–May 3, 2026 — Unavailable May 4, 2026–May 31, 2026 — Unavailable Jun 1, 2026–Jun 28, 2026 2 Partial; excluded Jun 29, 2026–Jul 26, 2026 3 Within stored history Jul 27, 2026–Aug 23, 2026 4 Within stored history Aug 24, 2026–Sep 20, 2026 4 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 3 Within stored history
Congress purchases · Within earlier range This count falls within the range of the 12 earlier comparable periods in this view. Earlier median: 0; range: 0–1.
Congress purchases: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 0 Within stored history Nov 17, 2025–Dec 14, 2025 0 Within stored history Dec 15, 2025–Jan 11, 2026 0 Within stored history Jan 12, 2026–Feb 8, 2026 1 Within stored history Feb 9, 2026–Mar 8, 2026 0 Within stored history Mar 9, 2026–Apr 5, 2026 0 Within stored history Apr 6, 2026–May 3, 2026 0 Within stored history May 4, 2026–May 31, 2026 1 Within stored history Jun 1, 2026–Jun 28, 2026 0 Within stored history Jun 29, 2026–Jul 26, 2026 1 Within stored history Jul 27, 2026–Aug 23, 2026 1 Within stored history Aug 24, 2026–Sep 20, 2026 0 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 0 Within stored history
Congress sales · Sparse history Only 1 of 12 earlier periods had activity. That is too little recurring activity to label this count unusual. Earlier median: 0; range: 0–1.
Congress sales: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 0 Within stored history Nov 17, 2025–Dec 14, 2025 0 Within stored history Dec 15, 2025–Jan 11, 2026 0 Within stored history Jan 12, 2026–Feb 8, 2026 0 Within stored history Feb 9, 2026–Mar 8, 2026 0 Within stored history Mar 9, 2026–Apr 5, 2026 0 Within stored history Apr 6, 2026–May 3, 2026 0 Within stored history May 4, 2026–May 31, 2026 0 Within stored history Jun 1, 2026–Jun 28, 2026 0 Within stored history Jun 29, 2026–Jul 26, 2026 0 Within stored history Jul 27, 2026–Aug 23, 2026 1 Within stored history Aug 24, 2026–Sep 20, 2026 0 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 0 Within stored history
How to read this comparison The median is the middle count in up to 12 earlier, non-overlapping 28-day periods; the range runs from the smallest to the largest count. The latest period is excluded from both. A comparison needs at least 6 earlier periods, including 3 with activity. The feed’s latest disclosure must be within 7 days of the current period’s end. This freshness check does not verify complete collection.
Insiders include individuals and reporting entities; only purchase and sale codes enter this view. Congress counts reporting members, including their disclosed family transactions. The same filer can appear in purchases and sales, so these categories should not be added into a net count.
These are stored disclosures, not a complete measure of trading. Reporting delays and collection gaps can change the comparison. More activity does not identify a motive or predict a stock’s return.
Company timeline
What has been happening? May 1, 2026–Oct 16, 2026. Select a month in a category to inspect its records.
Company filings May 8 Jun — Jul — Aug — Sep — Oct —
Insiders May 2 Jun 7 Jul 6 Aug 20 Sep 9 Oct 6
Public officials May 1 Jun — Jul 1 Aug 2 Sep — Oct —
FDA & trials May 3 Jun 6 Jul 2 Aug 6 Sep 5 Oct —
Owners & lobbying May — Jun — Jul 1 Aug — Sep — Oct —
Company filings · May 2026 Filed May 20, 2026 Filed May 20, 2026 Filed May 20, 2026 Filed May 20, 2026 Filed May 7, 2026 3 more on file are not listed here.
Insiders · Aug 2026 Disclosed Aug 27, 2026 Disclosed Aug 27, 2026 Disclosed Aug 27, 2026 Disclosed Aug 27, 2026 Filed Aug 26, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 18, 2026 Disclosed Aug 18, 2026 Disclosed Aug 18, 2026 7 more on file are not listed here. See that month’s insider trades →
Insiders · Sep 2026 Disclosed Sep 16, 2026 Disclosed Sep 16, 2026 Disclosed Sep 16, 2026 Disclosed Sep 16, 2026 Filed Sep 15, 2026 Filed Sep 15, 2026 Disclosed Sep 2, 2026 Disclosed Sep 2, 2026 Disclosed Sep 2, 2026 Insiders · Oct 2026 Disclosed Oct 16, 2026 Disclosed Oct 16, 2026 Filed Oct 15, 2026 Filed Oct 15, 2026 Disclosed Oct 2, 2026 Disclosed Oct 2, 2026 Public officials · Jul 2026 Disclosed Jul 21, 2026 Public officials · Aug 2026 Disclosed Aug 5, 2026 Disclosed Aug 5, 2026 FDA & trials · May 2026 3 on file. This page lists only the newest records.
FDA & trials · Jun 2026 6 on file. This page lists only the newest records.
FDA & trials · Jul 2026 2 on file. This page lists only the newest records.
FDA & trials · Aug 2026 6 on file. This page lists only the newest records.
FDA & trials · Sep 2026 Record date Sep 18, 2026 Record date Sep 18, 2026 Record date Sep 18, 2026 Record date Sep 18, 2026 Record date Sep 8, 2026 Owners & lobbying · Jul 2026 Record date Jul 19, 2026 All 42 records in this snapshot Disclosed Oct 16, 2026 Disclosed Oct 16, 2026 Filed Oct 15, 2026 Filed Oct 15, 2026 Disclosed Oct 2, 2026 Disclosed Oct 2, 2026 Record date Sep 18, 2026 Record date Sep 18, 2026 Record date Sep 18, 2026 Record date Sep 18, 2026 Disclosed Sep 16, 2026 Disclosed Sep 16, 2026 Disclosed Sep 16, 2026 Disclosed Sep 16, 2026 Filed Sep 15, 2026 Filed Sep 15, 2026 Record date Sep 8, 2026 Disclosed Sep 2, 2026 Disclosed Sep 2, 2026 Disclosed Sep 2, 2026 Disclosed Aug 27, 2026 Disclosed Aug 27, 2026 Disclosed Aug 27, 2026 Disclosed Aug 27, 2026 Filed Aug 26, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 21, 2026 Disclosed Aug 18, 2026 Disclosed Aug 18, 2026 Disclosed Aug 18, 2026 Disclosed Aug 5, 2026 Disclosed Aug 5, 2026 Disclosed Jul 21, 2026 Record date Jul 19, 2026 Filed May 20, 2026 Filed May 20, 2026 Filed May 20, 2026 Filed May 20, 2026 Filed May 7, 2026 Month counts include every record on file. The lists show the newest records on this page. A dash means none on file that month. Trades use disclosure dates; contract dates follow the source record. Nearby events do not establish the cause of a price move.
Who's buying and selling · last 90 days Company insiders 0 buys · 11 sells (26 filed lots) · $15.9M sold
▼ SELL Andrew D Dickinson Chief Financial Officer GILD Gilead Sciences, Inc. $469K disclosed Oct 16 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $469K disclosed Oct 16 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $446K disclosed Oct 2 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $1.8M disclosed Oct 2 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $116K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Andrew D Dickinson Chief Financial Officer GILD Gilead Sciences, Inc. $436K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $230K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $87.2K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $236K disclosed Sep 2 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $1.2M disclosed Sep 2 · filed 1 day after the trade See every insider trade on GILD → Filings & events Company filings (8-K) 56 Events the company must report to the SEC within days — results, deals, departures, restatements.
What it files 8-Ks about Quarterly or yearly results · item 2.02 9 Other events · item 8.01 5 Shared information with investors · item 7.01 5 Directors or officers joined, left or got new pay · item 5.02 5 Signed a major agreement · item 1.01 4 Took on new debt · item 2.03 2 Filing red flags 15 Warning signs in the company's own SEC filings — going-concern doubts, control weaknesses, staff comment letters, late filings, restatements, Wells notices, clinical holds, dividend cuts.
FDA and clinical trials 116 Drug approvals, recalls, clinical-trial updates and FDA advisory meetings.
Sep 18, 2026 Clinical trial stopped early: Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin ↗ Phase 2 Sep 18, 2026 Clinical trial completed: Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes ↗ Phase 2 Sep 18, 2026 Clinical trial completed: Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout ↗ Phase 2 Sep 18, 2026 Clinical trial completed: Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout ↗ Phase 2 Sep 8, 2026 Clinical trial stopped early: Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection ↗ Phase 3 Lobbying 90 Lobbying reports filed with the Senate for the company.
$19.1M across 90 reports
Issues named in the most reports Jul 19, 2026 Lobbying for Tiber Creek Group On Behalf Of Gilead Sciences, Inc. ↗ $30K · by B Hall Strategies, LLC Apr 9, 2026 Lobbying for Tiber Creek Group On Behalf Of Gilead Sciences, Inc. ↗ $30K · by B Hall Strategies, LLC Jan 19, 2026 Lobbying for Tiber Creek Group On Behalf Of Gilead Sciences, Inc. ↗ $30K · by B Hall Strategies, LLC Oct 20, 2025 Lobbying for Tiber Creek Group On Behalf Of Gilead Sciences, Inc. ↗ $30K · by B Hall Strategies, LLC Jul 21, 2025 Lobbying for Tiber Creek Group On Behalf Of Gilead Sciences, Inc. ↗ $30K · by B Hall Strategies, LLC Planned insider sales (Form 144) 87 Notices insiders file before they sell certain shares, such as ones they got straight from the company.
9 in the last 90 days · 87 notices on file
The notices on file don't give the sale's size; each sale shows up under company insiders once it is reported.
5% owners (13D / 13G) 2 Investors who reported owning 5% or more — 13D for owners who may push for changes, 13G for owners who just hold.
Push for changes, or just hold? Filed by Vanguard Capital Management LLC · Fmr LLC
Biggest named funds (13F) The largest GILD holdings among the well-known funds whose quarterly 13F filings we read — opens here.
Every disclosed trade on GILD ▼ SELL Andrew D Dickinson Chief Financial Officer GILD Gilead Sciences, Inc. $469K disclosed Oct 16 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $469K disclosed Oct 16 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $446K disclosed Oct 2 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $1.8M disclosed Oct 2 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $116K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Andrew D Dickinson Chief Financial Officer GILD Gilead Sciences, Inc. $436K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $230K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $87.2K disclosed Sep 16 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $236K disclosed Sep 2 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $1.2M disclosed Sep 2 · filed 1 day after the trade ▼ SELL Daniel Patrick O'Day Chairman & CEO GILD Gilead Sciences, Inc. $808K disclosed Sep 2 · filed 1 day after the trade ▼ SELL Anthony Welters Director GILD Gilead Sciences, Inc. $1M disclosed Aug 27 · filed 1 day after the trade ▼ SELL Anthony Welters Director GILD Gilead Sciences, Inc. $462K disclosed Aug 27 · filed 1 day after the trade ▼ SELL Anthony Welters Director GILD Gilead Sciences, Inc. $685K disclosed Aug 27 · filed 1 day after the trade ▼ SELL Anthony Welters Director GILD Gilead Sciences, Inc. $504K disclosed Aug 27 · filed 1 day after the trade ▼ SELL Jeffrey Bluestone Director GILD Gilead Sciences, Inc. $242K disclosed Aug 21 · filed 1 day after the trade ▼ SELL Jeffrey Bluestone Director GILD Gilead Sciences, Inc. $3.8K disclosed Aug 21 · filed 1 day after the trade ▼ SELL Jeffrey Bluestone Director GILD Gilead Sciences, Inc. $167K disclosed Aug 21 · filed 1 day after the trade ▼ SELL Jeffrey Bluestone Director GILD Gilead Sciences, Inc. $263K disclosed Aug 21 · filed 1 day after the trade ▼ SELL Jeffrey Bluestone Director GILD Gilead Sciences, Inc. $49K disclosed Aug 21 · filed 1 day after the trade ▼ SELL Andrew D Dickinson Chief Financial Officer GILD Gilead Sciences, Inc. $415K disclosed Aug 18 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $1.6M disclosed Aug 18 · filed 1 day after the trade ▼ SELL Johanna Mercier Chief Comm & Corp Aff Officer GILD Gilead Sciences, Inc. $2.3M disclosed Aug 18 · filed 1 day after the trade ▲ BUY Tommy Tuberville Rep · Senate · AL GILD Gilead Sciences, Inc. $1K–$15K disclosed Aug 5 · filed 817 days after the trade · late 1 rule fired ▼ SELL Tommy Tuberville Rep · Senate · AL GILD Gilead Sciences, Inc. $1K–$15K disclosed Aug 5 · filed 819 days after the trade · late 1 rule fired See all 75 trades on GILD → People & votes Which members of Congress traded GILD, sponsored bills that touch it and voted on them — opens here.